logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Sakar Healthcare Ltd

Sakar Healthcare

Small Cap•325 Employees•IPO 2016
Current Price
₹515.30
-0.35 (-0.07%)Updated
NSE :SAKAR
BSE :
Sector :Pharmaceuticals
Today's Range
492.2
₹515.30
indicator
519.15
52 Week Range
52W Low₹220.41
52W High₹577.95
₹515.30
indicator
Downside133.79%
Upside12.16%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹1,062.05 Cr
Market Cap
Total market value of company
P/E Ratio
42.11
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
2.63
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹11.45
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
3.50%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
8.54%
ROCE
Return on Capital Employed. >15% is good
Net Margin
10.92%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
4.52%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
16.44%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
28.20%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
93.80%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.30
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹130.06
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
52.90%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Robust quarterly profit growth of 93.80% indicates strong operational performance.
  • •Healthy quarterly sales growth of 28.20% reflects increasing market demand.

Weaknesses

5 points
  • •Low Return on Equity (ROE) at 6.48% suggests insufficient shareholder returns.
  • •Return on Capital Employed (ROCE) at 8.54% indicates capital inefficiency.

Opportunities

5 points
  • •Growing global demand for healthcare products and services.
  • •Substantial room to expand market share within the pharmaceutical sector.

Threats

5 points
  • •Highly competitive pharmaceutical industry threatens market share and pricing power.
  • •Stringent, evolving regulatory landscape could increase compliance costs and delays.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Aarsh S. Shah
27 Dec 202431 Dec 202414.07 L
1.00 L
₹288BUY
Sanjay S. Shah
27 Dec 202431 Dec 20241.00 Cr
1.00 L
₹288BUY

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹579.47+₹64.17+12.45%
R3₹552.52+₹37.22+7.22%
R2₹535.83+₹20.53+3.98%
R1₹525.57+₹10.27+1.99%
PIVOT₹508.88-6.42-1.25%
CURRENT₹515.30--
S1₹444.72-₹70.58-13.70%
S2₹471.67-₹43.63-8.47%
S3₹481.93-₹33.37-6.48%
S4₹498.62-₹16.68-3.24%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.51L
(02 Apr 2026)
-35.9% vs avg
Delivery %
37.2%
(02 Apr 2026)
-9.0% vs avg
Avg Volume (20D)
0.80L
(04 Mar - 02 Apr)
20-day average
Avg Delivery %
46.2%
(04 Mar - 02 Apr)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Wanbury Ltd
1197.00 %
Highest Dividend Yield
Kopran Ltd
2.26 %

Peer Comparison

Company Name
ANUHPHR
Anuh Pharma Ltd
BAJAJHCARE
Bajaj Healthcare Ltd
BETA
Beta Drugs Ltd
INDSWFTLAB
Ind-Swift Laboratories Ltd
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
KOPRAN
Kopran Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
NGLFINE
NGL Fine Chem Ltd
SIGACHI
Sigachi Industries Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SYNCOMF
Syncom Formulations (India) Ltd
THEMISMED
Themis Medicare Ltd
TTKHLTCARE
TTK Healthcare Ltd
VENUSREM
Venus Remedies Ltd
WANBURY
Wanbury Ltd

About

SAKAR

Sakar Healthcare Ltd

Sakar Healthcare Limited is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical products. Their operations encompass the entire production process, from initial research and development to final product marketing and distribution. The company's commitment to a wide spectrum of therapeutic areas allows them to cater to a broad patient base and market demand.

The company's product portfolio is extensive and includes various dosage forms to accommodate diverse patient needs and treatment preferences. These forms include liquid orals, tablets, capsules, dry powder syrups, dry powder injections, liquid injectables (SVP) in ampoules and vials, lyophilized injections, and oral solid dosages. This breadth of dosage forms allows for flexibility in administration and potentially improved patient compliance.

Sakar Healthcare's product offerings span a considerable number of therapeutic areas, indicating a wide range of medical conditions addressed by their formulations. These areas include antacids, antimalarials, anticoagulants, laxatives, anthelmintics, bronchodilators, anesthetics, antidepressants, sedatives, adrenergics, anti-infectives, diuretics, oxytocics, analgesics, antiemetics, antipsychotics, antifungals, PPIs, anticonvulsants, anti-inflammatories, antihistamines, and multivitamins. This diversified portfolio demonstrates a commitment to serving a wide range of patient needs.

Beyond the domestic Indian market, Sakar Healthcare actively participates in international trade, exporting its products to several key regions globally. These export destinations encompass Southeast Asia, other parts of Asia, various African countries (both Anglophone and Francophone), the Middle East and North Africa (MENA) region, and even the United States. This international reach significantly expands the company's market presence and potential for growth.

Established in 2004 and headquartered in Ahmedabad, India, Sakar Healthcare Limited has a history of providing pharmaceutical solutions. Their integrated approach, encompassing research, development, manufacturing, and marketing, positions them as a significant player within the Indian pharmaceutical industry and beyond, through its international exports. The company's success rests on its broad product portfolio, diverse therapeutic coverage, and global market reach.

COMPANY FACTS - SAKAR

Registered Address

406,Silver Oaks Comm. Complex, Opp. Arun Society, Paldi

Ahmedabad

GUJARAT

IN

Tel: 917926584655

Website:https://www.sakarhealthcare.com/

Investor Relations:http://www.sakarhealthcare.com/annual-report.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 325

IPO Date: 14/10/2016

MANAGEMENT - SAKAR

Mr. Sanjay Shah

Chairman of the Board, Managing Director

Mr. Dharmesh Thaker

Chief Financial Officer

Mr. Sudhir Ghule

Chief Operating Officer

Mr. Bharat Soni

Compliance Officer, Company Secretary

Mr. Aarsh Shah

Joint Managing Director, Director

Mr. Sunil Marathe

Whole Time Director - Technical

Ms. Vishalakshi Chandramouli

Non-Executive Non-Independent Director

Ms. Rita Shah

Non-Executive Director

Ms. Reeya Kothari

Independent Director

Ms. Hiral Patel

Independent Director

Ms. Megha Samdani

Independent Director

Mr. Jignesh Parikh

Additional Non-Executive Independent Director

Investor Questions Answered

Sakar Healthcare Ltd (SAKAR) Stock FAQs

Get answers to the most common questions about Sakar Healthcare Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Sakar Healthcare Ltd (SAKAR) is ₹515.3. Today, the stock has declined by ₹0.35 (0.07%), trading in a range of ₹492.2 to ₹519.15. The stock opened at ₹515 with a trading volume of 51,371 shares.
Sakar Healthcare Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,062.05 crores, P/E ratio of 42.11, ROE of 3.50%, and ROCE of 8.54%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Sakar Healthcare Ltd (SAKAR) is ₹577.95, while the 52-week low is ₹220.41. Currently trading at ₹515.3, the stock is 82.5% away from its 52-week low and 10.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Sakar Healthcare Ltd stock at ₹515.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 42.11 and P/B ratio of N/A. Today's performance shows a loss of 0.07%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Sakar Healthcare Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹515.3, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Sakar Healthcare Ltd's key financial metrics include: P/E Ratio: 42.11, P/B Ratio: N/A, ROE: 3.50%, ROCE: 8.54%, Dividend Yield: 0.00%, EPS: ₹11.45, Book Value: ₹130.06, Debt-to-Equity: 0.30, and Current Ratio: N/A. The company's market cap stands at ₹1,062.05 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Sakar Healthcare Ltd stock opened at ₹515 and is currently trading at ₹515.3, showing a decline of ₹0.35 (0.07%). The intraday high is ₹519.15 and low is ₹492.2. The trading volume stands at 51,371 shares, indicating moderate market participation today.
Sakar Healthcare Ltd has a Price-to-Earnings (P/E) ratio of 42.11, which means investors are willing to pay ₹42.11 for every ₹1 of earnings. With an EPS of ₹11.45, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Sakar Healthcare Ltd has a market capitalization of ₹1,062.05 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹515.3) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Sakar Healthcare Ltd has a book value of ₹130.06 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹515.3, which is 296.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Sakar Healthcare Ltd has a Return on Equity (ROE) of 3.50% and Return on Capital Employed (ROCE) of 8.54%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Sakar Healthcare Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Sakar Healthcare Ltd has a debt-to-equity ratio of 0.30, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Sakar Healthcare Ltd has an Earnings Per Share (EPS) of ₹11.45, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹515.3 and P/E ratio of 42.11, investors are paying 42.11 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Sakar Healthcare Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Sakar Healthcare Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Sakar Healthcare Ltd stock, consider: 1) Fundamental Analysis - Review P/E (42.11), ROE (3.50%), debt-to-equity (0.30), and growth rates. 2) Technical Analysis - Check 52-week range (₹220.41 - ₹577.95), moving averages, and chart patterns. 3) Valuation - Compare current price (₹515.30) with book value (₹130.06) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Sakar Healthcare Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹515.3 is 5053x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Sakar Healthcare Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹220.41 - ₹577.95). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.30 indicates leverage. 4) Liquidity Risk - Based on trading volume of 51,371 shares. 5) Valuation Risk - P/E of 42.11 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Sakar Healthcare Ltd operates in the industry with key metrics: P/E ratio of 42.11, ROE of 3.50%, market cap of ₹1,062.05 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.30), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Sakar Healthcare Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹515.3, with a 52-week range of ₹220.41 to ₹577.95. Based on fundamentals like P/E (42.11), ROE (3.50%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Sakar Healthcare Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹515.30. 2) Fundamental Deterioration - Declining ROE (currently 3.50%), increasing debt (D/E: 0.30), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Sakar Healthcare Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.